Back to today’s briefing

Story perspectives

FDA Lifts Clozapine Restrictions, Boosts Schizophrenia Treatment Access

6/17/2025

33 7

Summary

Story summary

On June 13, 2025, the FDA lifted restrictions on clozapine, opening doors for schizophrenia treatment despite lingering risks. In response, the Schizophrenia & Psychosis Action Alliance is set to roll out educational programs, empowering prescribers to navigate clozapine use and ultimately fostering better patient care while combating the stigma of serious mental illness.

1 of 1

Story summary

On June 13, 2025, the FDA lifted restrictions on clozapine, opening doors for schizophrenia treatment despite lingering risks. In response, the Schizophrenia & Psychosis Action Alliance is set to roll out educational programs, empowering prescribers to navigate clozapine use and ultimately fostering better patient care while combating the stigma of serious mental illness.